CJC-1295 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is researched primarily for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects. The 'no DAC' version is preferred over CJC-1295 DAC because it preserves natural pulsatile GH release rather than creating a sustained elevation that can desensitize receptors and suppress feedback loops. It belongs to the Growth Hormone Releasing Hormone (GHRH) analog category of compounds.
What Is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability.
The 'no DAC' version is preferred over CJC-1295 DAC because it preserves natural pulsatile GH release rather than creating a sustained elevation that can desensitize receptors and suppress feedback loops. It has attracted significant research interest for its potential effects on increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
How Does CJC-1295 Produce These Benefits?
CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, stimulating growth hormone synthesis and pulsatile secretion through the cAMP-PKA signaling cascade. The 'no DAC' version has a shorter half-life, resulting in more natural GH pulses that mimic the body's endogenous rhythm rather than creating sustained supraphysiological levels.
This multi-pathway activity is why CJC-1295 shows potential across several different applications rather than being limited to a single use case.
Can CJC-1295 Help With Increased Growth Hormone Secretion?
Research suggests CJC-1295 may support increased growth hormone secretion through its growth hormone releasing hormone (ghrh) analog activity. Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
Protocols targeting increased growth hormone secretion typically use 100-300 mcg administered 1-3 times daily, typically before bed for 8-12 weeks, often paired with Ipamorelin.
Can CJC-1295 Help With Improved Body Composition?
Research suggests CJC-1295 may support improved body composition through its growth hormone releasing hormone (ghrh) analog activity. Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
Protocols targeting improved body composition typically use 100-300 mcg administered 1-3 times daily, typically before bed for 8-12 weeks, often paired with Ipamorelin.
Can CJC-1295 Help With Better Sleep Quality?
Research suggests CJC-1295 may support better sleep quality through its growth hormone releasing hormone (ghrh) analog activity. Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
Protocols targeting better sleep quality typically use 100-300 mcg administered 1-3 times daily, typically before bed for 8-12 weeks, often paired with Ipamorelin.
Can CJC-1295 Help With Enhanced Recovery?
Research suggests CJC-1295 may support enhanced recovery through its growth hormone releasing hormone (ghrh) analog activity. Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
Protocols targeting enhanced recovery typically use 100-300 mcg administered 1-3 times daily, typically before bed for 8-12 weeks, often paired with Ipamorelin.
Can CJC-1295 Help With Anti-Aging Effects?
Research suggests CJC-1295 may support anti-aging effects through its growth hormone releasing hormone (ghrh) analog activity. Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
Protocols targeting anti-aging effects typically use 100-300 mcg administered 1-3 times daily, typically before bed for 8-12 weeks, often paired with Ipamorelin.
Can Stacking Enhance CJC-1295 Benefits?
The gold standard stack is CJC-1295 + Ipamorelin — GHRH + GHRP together produce GH pulses far greater than either alone, through synergistic pituitary stimulation via two distinct receptor pathways.
See our CJC-1295 stacking guide for detailed combination protocols.
What Is the Bottom Line on CJC-1295 Benefits?
CJC-1295 is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects. The evidence base includes: Clinical research demonstrates significant increases in GH and IGF-1 levels in human subjects. Studies show improved body composition with increased lean mass and reduced body fat, particularly when combined with GHRP peptides like Ipamorelin.
CJC-1295 is not fda-approved. research chemical status. banned by wada. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
CJC-1295 : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 Dosage Guide
- CJC-1295 Side Effects
- CJC-1295 Stacking Guide
- CJC-1295 Cycle Guide
- CJC-1295 Research
- Ipamorelin Complete Guide
Calculate Your CJC-1295 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295.
Open Calculator →Research-Grade Sourcing
If you're going to research CJC-1295, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
What is the recommended CJC-1295 dosage?
Common dosages: 100-300 mcg administered 1-3 times daily, typically before bed via subcutaneous injection. Cycle length: 8-12 weeks, often paired with Ipamorelin. Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
Is CJC-1295 safe?
CJC-1295 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical status. Banned by WADA. All research should follow appropriate safety protocols.